<DOC>
	<DOCNO>NCT02989935</DOCNO>
	<brief_summary>This study examine effect ultra long act beta agonist/corticosteroid bronchodilator combination fluticasone furoate/vilanterol trifenatate , respiratory muscle ventilation adult severe bronchitis emphysema ( COPD ) .</brief_summary>
	<brief_title>RELVAR Effects Parasternal Muscle Activity , Diaphragm , Ventilation Severe COPD</brief_title>
	<detailed_description>In adult severe , minimally reversible bronchitis emphysema ( COPD ) , progressive hyperinflation lung associate flatten inefficiency major respiratory muscle , diaphragm . These change limit physical activity exercise , provoke shortness breath - dyspnea . These debilitate symptom often significantly lessen ultra long act combination bronchodilator , even adult bronchodilator produce measurable improvement either airflow lung hyperinflation . This symptomatic improvement adult severe , minimally reversible COPD may occur direct benefit bronchodilator respiratory muscle ventilation . This study examine effect ultra long act bronchodilator fluticasone furoate/vilanterol trifenatate upon upper anterior chest wall respiratory muscle ( parasternals ) , diaphragm , breathe pattern .</detailed_description>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>ambulatory , stable severe COPD ( GOLD Class IIIIV ) long act bronchodilator therapy compliant use prescribed medication fit minor surgical procedure include intravenous sedation hypersensitivity milk proteins hypersensitive fluticasone furoate/vilanterol formulation angina substantial cardiovascular risk exacerbation COPD within precede 2 month significant nonrespiratory system disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>respiratory muscle</keyword>
	<keyword>bronchodilator</keyword>
</DOC>